Rapporto sull’analisi delle dimensioni del mercato e dell’analisi delle quote del mercato Diagnostica del cancro al fegato | Previsioni 2031

  • Report Code : TIPRE00003017
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 181
Buy Now

Si prevede che il mercato della diagnostica del cancro al fegato raggiungerà i 15.951,77 milioni di dollari entro il 2028 rispetto ai 9.323,14 milioni di dollari del 2021. Si stima che il mercato crescerà a un CAGR dell'8,0% nel periodo dal 2021 al 2028.

Il cancro al fegato inizia nelle cellule del fegato. Nel fegato possono formarsi diversi tipi di cancro. Il carcinoma epatocellulare è considerato il cancro del fegato più comune e inizia nell'epatocita. Secondo l’American Society of Clinical Oncology (ASCO), circa l’80% dei tumori primari del fegato negli adulti sono carcinomi epatocellulari. Altri tipi di cancro al fegato includono l’epatoblastoma e il colangiocarcinoma intraepatico. Questi sono considerati meno comuni. La diagnostica del cancro al fegato comprende tecniche utilizzate per l'identificazione e la conferma del cancro al fegato.

Approfondimenti strategici

La crescita del mercato della diagnostica del cancro al fegato è attribuita alla crescente prevalenza del cancro al fegato e ai crescenti investimenti in ricerca e sviluppo. nello sviluppo di nuovi test diagnostici. D'altra parte, il costo elevato delle soluzioni diagnostiche per il cancro al fegato tecnologicamente avanzate ostacola la crescita del mercato.

Regioni redditizie nel mercato della diagnostica del cancro al fegato


Approfondimenti di mercato< br />Crescenti investimenti in ricerca e sviluppo nello sviluppo di nuovi test diagnostici

La capacità di diagnosticare con precisione la progressione del cancro al fegato è fondamentale per selezionare l'opzione di trattamento appropriata. Inoltre, diverse aziende e organizzazioni hanno intrapreso enormi iniziative per sviluppare e implementare soluzioni innovative per l’identificazione precoce di questa malattia in risposta alla crescente domanda. Ad esempio, nel marzo 2020, il punteggio Elecsys GALAD di Roche Holding AG ha ricevuto dalla Food and Drug Administration statunitense lo status di dispositivo rivoluzionario per la diagnosi precoce di una forma avanzata di cancro al fegato. Il calcolatore dell'azienda farmaceutica svizzera combina fattori tra cui età, sesso e risultati dei biomarcatori per rilevare il carcinoma epatocellulare in stadio iniziale, che è la forma più comune di cancro al fegato. Inoltre, il punteggio Elecsys GALAD è progettato per supportare i medici fornendo loro una diagnosi tempestiva e accurata del carcinoma epatocellulare. La spesa per ricerca e sviluppo (R&S) nel 2021 è stata di 14,65 miliardi di dollari e nel 2020 è stata di 13,17 miliardi di dollari. La spesa in ricerca e sviluppo è cresciuta del 14% su base core, in F. Hoffmann-La Roche Ltd, principalmente guidata da investimenti in fase avanzata in oncologia, oftalmologia e assistenza sanitaria personalizzata. Nel 2021, l'investimento in ricerca e sviluppo nella divisione diagnostica è stato di 1.878,92 milioni di dollari. Allo stesso modo, nel novembre 2019, EXACT Sciences Corporation ha ricevuto la designazione rivoluzionaria dalla Food and Drug Administration (FDA) per il suo test basato sul sangue per la diagnosi precoce del cancro al fegato. Inoltre, nel giugno 2020, gli scienziati del National Institutes of Health (NIH) hanno sviluppato esami del sangue per contribuire a migliorare lo screening del cancro al fegato, guidati da ricercatori del National Cancer Institute (NCI). Inoltre, nel giugno 2019, i ricercatori della Johns Hopkins University hanno progettato CancerSEEK, un test di biopsia liquida. Il test è stato progettato per diagnosticare più tumori, tra cui quello dello stomaco, del fegato, delle ovaie e dell’esofago, in una fase precoce, facilitando il trattamento precoce. Pertanto, i crescenti investimenti in ricerca e sviluppo e lo sviluppo di test diagnostici per l'individuazione del cancro al fegato stanno guidando il mercato della diagnostica del cancro al fegato.

Approfondimenti basati sui tipi

La diagnostica globale del cancro al fegato Il mercato, in base al tipo, è segmentato in test di laboratorio, endoscopia, imaging, biopsia e altri. Il mercato per il segmento dei test di laboratorio è ulteriormente segmentato in esami del sangue e biomarcatori. Il segmento dei test di laboratorio deteneva la quota maggiore del mercato nel 2021. Tuttavia, si prevede che il segmento dell’imaging registrerà un CAGR dell’8,5% nel mercato durante il periodo di previsione.  

Mercato della diagnostica del cancro al fegato, per tipo: – 2021 e 2028


Approfondimenti basati sull'utente finale

In base all'utente finale, il mercato globale della diagnostica del cancro al fegato è segmentato in ospedali e laboratori diagnostici, istituti accademici e di ricerca, e laboratori CRO. Il segmento degli ospedali e dei laboratori diagnostici ha detenuto la quota maggiore del mercato nel 2021 poiché gli ospedali forniscono strutture sanitarie attraverso apparecchiature scientifiche specializzate. Un team di personale qualificato viene incaricato di affrontare, indagare e ripristinare i problemi associati alla moderna scienza medica in ospedale. Vari gruppi di ricerca medica lavorano costantemente per introdurre tecnologie innovative legate ai metodi diagnostici e ad altre attività in campo medico. I pazienti generalmente preferiscono che l'ospedale si sottoponga al trattamento del cancro al fegato a causa della disponibilità di opzioni terapeutiche avanzate. Gli ospedali sono il punto di cura per i pazienti. Inoltre, si prevede che lo stesso segmento registrerà un CAGR del mercato dell'8,5% durante il periodo di previsione.

Il lancio e l'approvazione dei prodotti sono strategie comunemente adottate dalle aziende per espandere la propria presenza globale e i portafogli di prodotti per dominare il mercato. quota di mercato della diagnostica del cancro al fegato. Inoltre, gli operatori del mercato si concentrano sulla strategia di partnership per ampliare la propria clientela, che, a sua volta, consente loro di mantenere il proprio marchio a livello globale. Si prevede che la quota di mercato della diagnostica del cancro al fegato prospererà con lo sviluppo di nuovi prodotti innovativi da parte degli attori del mercato.

Profili aziendali

  • Abbott
  • BioMerieux SA
  • F. HOFFMANN-LA ROCHE LTD
  • Illumina, Inc.
  • Koninklijke Philips NV
  • QIAGEN
  • Siemens Healthineers AG
  • THERMO FISHER SCIENTIFIC INC.
  • GE Healthcare
  • Perspectum
  • Helio, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are liver cancer diagnostics?

The abnormal proliferation of cells in the body is referred to as cancer. Cancer of the liver starts in the cells of the liver. The liver can develop a variety of cancers. Hepatocellular carcinoma is the most prevalent type of liver cancer, and it starts in the hepatocyte. Some liver cancers can be detected through screening in persons who are at high risk but do not have symptoms, but most liver cancers are discovered when they produce symptoms. To detect liver disease, a series of blood tests known as liver function tests and imaging studies are employed.

What are the driving factors for the liver cancer diagnostics market across the globe?

Key factors that are driving the growth of this market are the rising prevalence of liver cancer and rising R&D investments for the development of novel diagnostic testing are expected to boost the market growth for liver cancer diagnostics over the years.

What is the market CAGR value of the liver cancer diagnostics market during the forecast period?

The CAGR value of the liver cancer diagnostics market during the forecasted period of 2021-2028 is 8.0%.

Which type led the liver cancer diagnostics market?

The laboratory tests segment held the largest share of the market in the global liver cancer diagnostics market and held the largest market share of 39.61% in 2021.

Which end user held the largest share in the liver cancer diagnostics market?

The hospitals and diagnostic laboratories segment dominated the global liver cancer diagnostics market and accounted for the largest market share of 48.56% in 2021.

Who are the key players in the Liver Cancer Diagnostics market?

The liver cancer diagnostics market majorly consists of players such as Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; Helio, Inc amongst others.

Which are the top companies that hold the market share in liver cancer diagnostics market?

Koninklijke Philips N.V. and Siemens Healthineers AG are the top two companies that hold huge market shares in the liver cancer diagnostics market.

Which region is expected to witness significant demand for the liver cancer diagnostics market in the coming years?

The North America region secures a substantial share of the global liver cancer diagnostics market. The growth of the market in the region is attributed by the rising prevalence of liver cancer. In North America, the US is the largest market for liver cancer diagnostics. The growth of this market is primarily driven by the growing prevalence of liver cancer diseases, technological advancements and developments in the US are going to accelerate the growth of this market in this country.

What is the COVID 19 impact on the Liver Cancer Diagnostics market in the coming years?

The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented problems to healthcare systems, and patients with liver cancer (LC) may have been particularly affected. COVID-19 may aggravate pre-existing chronic liver damage in HCC patients, complicating cancer treatment. Cancer patients, especially those who have just completed treatment, are at a higher risk of infection and have a poorer prognosis. The first wave of the COVID-19 epidemic had a huge influence on liver cancer patients' normal care. Patients' outcomes may have been considerably harmed as a result of changes to screening, diagnostic, and treatment algorithms. The benefits and drawbacks of the tactics used will be reported through ongoing data collecting and future analysis, assisting future decision-making. However, in the long run, as the vaccination schedule is established and the transmission rate decreases, healthcare systems will return to normal and is expected to experience increased demand for liver cancer diagnostics.

The List of Companies - Liver Cancer Diagnostic Market

  1. Abbott
  2. BioMerieux SA
  3. F. HOFFMANN-LA ROCHE LTD
  4. Illumina, Inc.
  5. Koninklijke Philips N.V
  6. QIAGEN
  7. Siemens Healthineers AG
  8. THERMO FISHER SCIENTIFIC INC.
  9. GE Healthcare
  10. Perspectum
  11. Helio, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports